Keratinocytes in psoriasis: Key players in the disease process

Psoriasis: Types, Triggers and Treatment Strategies

Volumn , Issue , 2013, Pages 1-54

  Helwa, Inas ^b   Gullotto, Meg ^b   Bollag, Wendy B ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b AUGUSTA UNIVERSITY   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892027431     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (268)

1. Hwa, C., E.A. Bauer, and D.E. Cohen, Skin biology. Dermatol. Ther., 2011. 24(5): p. 464-70.
2. Kim, B.E. and D.Y.M. Leung, Epidermal barrier in atopic dermatitis. Allergy Asthma and Immunology Researc., 2012. 4(1): p. 12-6.
3. Ramos-e-Silva, M. and C.d.-M.-C. Jacques, Epidermal barrier function and systemic diseases. Clinics in Dermatolog., 2012. 30(3): p. 277-9.
4. L., M.A., Skin, in Junqueira's basic histology (text and atlas), W.M.a.D. K., Editor. 2010, McGraw Companies: United States of America. p. 316-29.
5. Eckes, B., T. Krieg, B.V. Nusgens, and C.M. Lapiere, In vitro reconstituted skin as a tool for biology, pharmacology and therapy: A review. Wound Repair Regen., 1995. 3(3): p. 248-57.
6. Adams, M.P., D.G. Mallet, and G.J. Pettet, Active regulation of the epidermal calcium profile. Journal of Theoretical Biology, 2012. 301: p. 112-21.
7. Schon, M.P. and W.H. Boehncke, Medical progress -psoriasis. New England Journal of Medicin., 2005. 352(18): p. 1899-912.
8. Menon, G.K. and P.M. Elias, Ultrastructural-localization of calcium in psoriatic and normal human epidermis. Arch. Dermatol., 1991. 127(1): p. 57-63.
9. Li, L.W., R.W. Tucker, H. Hennings, and S.H. Yuspa, Chelation of intracellular ca2+ inhibits murine keratinocyte differentiation in-vitro. Journal of Cellular Physiolog., 1995. 163(1): p. 105-14.
10. Menon, G.K., P.M. Elias, S.H. Lee, and K.R. Feingold, Localization of calcium in murine epidermis following disruption and repair of the permeability barrier. Cell and Tissue Researc., 1992. 270(3): p. 503-12.
11. Menon, G.K., S. Grayson, and P.M. Elias, Ionic calcium reservoirs in mammalian epidermis -ultrastructural-localization by ion-capture cyto-chemistry. Journal of Investigative Dermatolog., 1985. 84(6): p. 508-12.
12. Komuves, L., Y. Oda, C.L. Tu, W.H. Chang, C.L. Ho-Pao, T. Mauro, and D.D. Bikle, Epidermal expression of the full-length extracellular calcium-sensing receptor is required for normal keratinocyte differentiation. Journal of Cellular Physiolog., 2002. 192(1): p. 45-54.
13. Oda, Y., C.L. Tu, W.H. Chang, D. Crumrine, L. Komuves, T. Mauro, P.M. Elias, and D.D. Bikle, The calcium sensing receptor and its alternatively spliced form in murine epidermal differentiation. Journal of Biological Chemistr., 2000. 275(2): p. 1183-90.
14. Hennings, H., D. Michael, C. Cheng, P. Steinert, K. Holbrook, and S.H. Yuspa, Calcium regulation of growth and differentiation of mouse epidermal-cells in culture. Cel., 1980. 19(1): p. 245-54.
15. Bikle, D.D. and S. Pillai, Vitamin-d, calcium, and epidermal differentiation. Endocrine Review., 1993. 14(1): p. 3-19.
16. Tu, C.L., D.A. Crumrine, M.Q. Man, W.H. Chang, H. Elalieh, M. You, P.M. Elias, and D.D. Bikle, Ablation of the calcium-sensing receptor in keratinocytes impairs epidermal differentiation and barrier function. Journal of Investigative Dermatolog., 2012. 132(10): p. 2350-9.
17. Celli, A., S. Sanchez, M. Behne, T. Hazlett, E. Gratton, and T. Mauro, The epidermal ca(2+) gradient: Measurement using the phasor representation of fluorescent lifetime imaging. Biophys. J., 2010. 98(5): p. 911-21.
18. Lee, S.H., S.K. Jeong, and S.K. Ahn, An update of the defensive barrier function of skin. Yonsei Medical Journa., 2006. 47(3): p. 293-306.
19. Dhitavat, J., R.J. Fairclough, A. Hovnanian, and S.M. Burge, Calcium pumps and keratinocytes: Lessons from darier's disease and hailey-hailey disease. British Journal of Dermatolog., 2004. 150(5): p. 821-8.
20. Savignac, M., A. Edir, M. Simon, and A. Hovnanian, Darier disease: A disease model of impaired calcium homeostasis in the skin. Biochimica Et Biophysica Acta-Molecular Cell Research, 2011. 1813(5): p. 1111-7.
21. Addor, F.A.S.A. and V. Aoki, Skin barrier in atopic dermatitis. Anais brasileiros de dermatologi., 2010. 85(2): p. 184-94.
22. Leuner, K., M. Kraus, U. Woelfle, H. Beschmann, C. Harteneck, W.H. Boehncke, C.M. Schempp, and W.E. Muller, Reduced trpc channel expression in psoriatic keratinocytes is associated with impaired differentiation and enhanced proliferation. PLoS On., 2011. 6(2): p. e14716.
23. Gudjonsson, J.E., A. Johnston, M. Dyson, H. Valdimarsson, and J.T. Elder, Mouse models of psoriasis. Journal of Investigative Dermatolog., 2007. 127(6): p. 1292-308.
24. Gudjonsson, J.E. and J.T. Elder, Psoriasis: An epidermal disease after all? European Journal of Human Genetics, 2006. 14(1): p. 2-4.
25. Roberson, E.D.O. and A.M. Bowcock, Psoriasis genetics: Breaking the barrier. Trends in Genetics, 26(9): p. 415-23.
26. Ockenfels, H.M., T. Schultewolter, G. Ockenfels, R. Funk, and M. Goos, The antipsoriatic agent dimethylfumarate immunomodulates t-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. British Journal of Dermatolog., 1998. 139(3): p. 390-5.
27. Perera, G.K., P. Di Meglio, and F.O. Nestle, Psoriasis, in Annual review of pathology: Mechanisms of disease, vol 7, A.K. Abbas, S.J. Galli, and P.M. Howley, Editors. 2012. p. 385-422.
28. Naldi, L. and G. Raho, Emerging drugs for psoriasis. Expert. Opin. Emerg. Drug., 2009. 14(1): p. 145-63.
29. Nast, A., W.-H. Boehncke, U. Mrowietz, H.-M. Ockenfels, S. Philipp, K. Reich, T. Rosenbach, A. Sammain, M. Schlaeger, M. Sebastian, W. Sterry, V. Streit, M. Augustin, R. Erdmann, J. Klaus, J. Koza, S. Mueller, H.-D. Orzechowski, S. Rosumeck, G. Schmid-Ott, T. Weberschock, and B. Rzany, S3-guidelines on the treatment of psoriasis vulgaris (english version). Update. Journal Der Deutschen Dermatologischen Gesellschaft, 2012. 10.
30. Menter, A., N.J. Korman, C.A. Elmets, S.R. Feldman, J.M. Gelfand, K.B. Gordon, A.B. Gottlieb, J.Y.M. Koo, M. Lebwohl, H.W. Lim, A.S. Van Voorhees, K.R. Beutner, and R. Bhushan, Guidelines of care for the management of psoriasis and psoriatic arthritis section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J. Am. Acad. Dermatol., 2009. 61(3): p. 451-85.
31. Raho, G., D.M. Koleva, L. Garattini, and L. Naldi, The burden of moderate to severe psoriasis: An overview. Pharmacoeconomic., 2012. 30(11): p. 1005-13.
32. Lowes, M.A., A.M. Bowcock, and J.G. Krueger, Pathogenesis and therapy of psoriasis. Natur., 2007. 445(7130): p. 866-73.
33. Gudjonsson, J.E. and J.T. Elder, Psoriasis: Epidemiology. Clinics in Dermatolog., 2007. 25(6): p. 535-46.
34. Levy, A.R., A.M. Davie, N.C. Brazier, F. Jivraj, L.E. Albrecht, D. Gratton, and C.W. Lynde, Economic burden of moderate to severe plaque psoriasis in canada. International Journal of Dermatolog., 2012. 51(12): p. 1432-40.
35. Villasenor-Park, J., D. Wheeler, and L. Grandinetti, Psoriasis: Evolving treatment for a complex disease. Cleveland Clinic Journal of Medicin., 2012. 79(6): p. 413-23.
36. Dogra, S. and I. Kaur, Childhood psoriasis. Indian Journal of Dermatology Venereology and Leprolog., 2010. 76(4): p. 357-65.
37. Benoit, S. and H. Hamm, Childhood psoriasis. Clin. Dermatol., 2007. 25(6): p. 555-62.
38. Augustin, M., G. Glaeske, M.A. Radtke, E. Christophers, K. Reich, and I. Schafer, Epidemiology and comorbidity of psoriasis in children. British Journal of Dermatolog., 2010. 162(3): p. 633-6.
39. De Jager, M.E.A., E. De Jong, A.W.M. Evers, P.C.M. Van De Kerkhof, and M.M.B. Seyger, The burden of childhood psoriasis. Pediatric. Dermatolog., 2011. 28(6): p. 736-7.
40. Griffiths, C.E.M. and J. Barker, Psoriasis 1 -pathogenesis and clinical features of psoriasis. Lance., 2007. 370(9583): p. 263-71.
41. Lebwohl, M., Psoriasis. Lance., 2003. 361(9364): p. 1197-204.
42. Nestle, F.O., D.H. Kaplan, and J. Barker, Mechanisms of disease: Psoriasis. New England Journal of Medicin., 2009. 361(5): p. 496-509.
43. Russell, A.S., W.P. Gulliver, E.J. Irvine, S. Albani, and J.P. Dutz, Quality of life in patients with immune-mediated inflammatory diseases. Journal of Rheumatology, 2011. 38: p. 7-19.
44. Rieder, E. and F. Tausk, Psoriasis, a model of dermatologic psychosomatic disease: Psychiatric implications and treatments. International Journal of Dermatolog., 2012. 51(1): p. 12-26.
45. Naldi, L. and L. Chatenoud, Psoriasis. N. Engl. J. Med., 2005. 353(8): p. 848-50; author reply -50.
46. Fortune, D.G., H.L. Richards, B. Kirby, K. McElhone, T. Markham, S. Rogers, C.J. Main, and C.E. Griffiths, Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch. Dermatol., 2003. 139(6): p. 752-6.
47. Rapp, S.R., S.R. Feldman, M.L. Exum, A.B. Fleischer, and D.M. Reboussin, Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol., 1999. 41(3): p. 401-7.
48. Schmitt, J.M. and D.E. Ford, Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatolog., 2006. 213(2): p. 102-10.
49. Kurd, S.K., A.B. Troxel, P. Crits-Christoph, and J.M. Gelfand, The risk of depression, anxiety, and suicidality in patients with psoriasis a population-based cohort study. Arch. Dermatol., 2010. 146(8): p. 891-5.
50. Garg, A. and D. Gladman, Recognizing psoriatic arthritis in the dermatology clinic. J. Am. Acad. Dermatol., 2010. 63(5): p. 733-48.
51. Chan, B., B. Hales, N. Shear, V. Ho, C. Lynde, Y. Poulin, and N. Mittmann, Work-related lost productivity and its economic impact on canadian patients with moderate to severe psoriasis. Journal of Cutaneous Medicine and Surger., 2009. 13(4): p. 192-7.
52. Alexandroff, A.B., M. Pauriah, R.D.R. Camp, C.C. Lang, A.D. Struthers, and D.J. Armstrong, More than skin deep: Atherosclerosis as a systemic manifestation of psoriasis. British Journal of Dermatolog., 2009. 161(1): p. 1-7.
53. Augustin, M., J.M. Alvaro-Gracia, M. Bagot, O. Hillmann, P.C. van de Kerkhof, G. Kobelt, M. Maccarone, L. Naldi, and H. Schellekens, A framework for improving the quality of care for people with psoriasis. J. Eur. Acad. Dermatol. Venereol., 2012. 26 Suppl 4: p. 1-16.
54. Flammer, A.J. and F. Ruschitzka, Psoriasis and atherosclerosis: Two plaques, one syndrome? European Heart Journal, 2012. 33(16): p. 1989-91.
55. Bens, G., F. Maccari, and E. Esteve, Psoriasis: A systemic disease. Presse Medical., 2012. 41(4): p. 338-48.
56. Scarpa, R., ew insights into the concept of psoriatic disease. Journal of Rheumatology, 2012. 39: p. 4-6.
57. Boehncke, W.-H., S. Boehncke, A.-M. Tobin, and B. Kirby, The 'psoriatic march': A concept of how severe psoriasis may drive cardiovascular comorbidity. Experimental Dermatolog., 2011. 20(4): p. 303-7.
58. Gelfand, J.M., E.D. Dommasch, D.B. Shin, R.S. Azfar, S.K. Kurd, X. Wang, and A.B. Troxel, The risk of stroke in patients with psoriasis. Journal of Investigative Dermatolog., 2009. 129(10): p. 2411-8.
59. Langan, S.M., N.M. Seminara, D.B. Shin, A.B. Troxel, S.E. Kimmel, N.N. Mehta, D.J. Margolis, and J.M. Gelfand, Prevalence of metabolic syndrome in patients with psoriasis: A population-based study in the united kingdom. Journal of Investigative Dermatolog., 2012. 132(3): p. 556-62.
60. Mehta, N.N., R.S. Azfar, D.B. Shin, A.L. Neimanns, A.B. Troxel, and J.M. Gelfand, Patients with severe psoriasis are at increased risk of cardiovascular mortality: Cohort study using the general practice research database. European Heart Journa., 2010. 31(8): p. 1000-6.
61. Mehta, N.N., Y.D. Yu, B. Saboury, N. Foroughi, P. Krishnamoorthy, A. Raper, A. Baer, J. Antigua, A.S. Van Voorhees, D.A. Torigian, A. Alavi, and J.M. Gelfand, Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by 18f -fluorodeoxyglucose positron emission tomography-computed tomography (fdg-pet/ct). Arch Dermatol, 2011. 147(9): p. 1031-9.
62. Li, W.Q., J.L. Han, J.E. Manson, E.B. Rimm, K.M. Rexrode, G.C. Curhan, and A.A. Qureshi, Psoriasis and risk of nonfatal cardiovascular disease in us women: A cohort study. British Journal of Dermatolog., 2012. 166(4): p. 811-8.
63. Gelfand, J.M., A.L. Neimann, D.B. Shin, X.M. Wang, D.J. Margolis, and A.B. Troxel, Risk of myocardial infarction in patients with psoriasis. Jama-Journal of the American Medical Association, 2006. 296(14): p. 1735-41.
64. Boehncke, S., S. Fichtlscherer, R. Salgo, J. Garbaraviciene, H. Beschmann, S. Diehl, K. Hardt, D. Thaci, and W.H. Boehncke, Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: Results of a prospective longitudinal pilot trial. Archives of Dermatological Researc., 2011. 303(6): p. 381-8.
65. Arumugam, R. and N.J. McHugh, Mortality and causes of death in psoriatic arthritis. Journal of Rheumatology, 2012. 39: p. 32-5.
66. Boehncke, W.H., S. Boehncke, A.M. Tobin, and B. Kirby, The 'psoriatic march': A concept of how severe psoriasis may drive cardiovascular comorbidity. Experimental Dermatolog., 2011. 20(4): p. 303-7.
67. Wilson, P.B., K.A. Bohjanen, S.J. Ingraham, and A.S. Leon, Psoriasis and physical activity: A review. Journal of the European Academy of Dermatology and Venereolog., 2012. 26(11): p. 1345-53.
68. Ahdout, J., J. Kotlerman, D. Elashoff, J. Kim, and M.W. Chiu, Modifiable lifestyle factors associated with metabolic syndrome in patients with psoriasis. Clin. Exp. Dermatol., 2012. 37(5): p. 477-83.
69. Herron, M.D., M. Hinckley, M.S. Hoffman, J. Papenfuss, C.B. Hansen, K.P. Callis, and G.G. Krueger, Impact of obesity and smoking on psoriasis presentation and management. Arch. Dermatol., 2005. 141(12): p. 1527-34.
70. Najarian, D.J. and A.B. Gottlieb, Connections between psoriasis and crohn's disease. J. Am. Acad. Dermatol., 2003. 48(6): p. 805-21.
71. Zeichner, J.A., Considerations when initiating psoriasis patients on biologic therapy. Journal of Drugs in Dermatolog., 2012. 11(5): p. S11-S4.
72. Gelfand, J.M., D.B. Shin, A.L. Neimann, X.M. Wang, D.J. Margolis, and A.B. Troxel, The risk of lymphoma in patients with psoriasis. Journal of Investigative Dermatolog., 2006. 126(10): p. 2194-201.
73. Nestle, F.O., D.H. Kaplan, and J. Barker, Psoriasis. N. Engl. J. Med., 2009. 361(5): p. 496-509.
74. Coimbra, S., A. Figueiredo, E. Castro, P. Rocha-Pereira, and A. Santos-Silva, The roles of cells and cytokines in the pathogenesis of psoriasis. Int. J. Dermatol., 2012. 51(4): p. 389-95; quiz 95-8.
75. Krueger, J.G. and A. Bowcock, Psoriasis pathophysiology: Current concepts of pathogenesis. Ann. Rheum. Dis., 2005. 64 Suppl 2: p. ii30-6.
76. Duffin, K.C., J. Woodcock, and G.G. Krueger, Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association. Dermatol. Ther., 2010. 23(2): p. 101-13.
77. Guinot, C., J. Latreille, M. Perrussel, N. Doss, L. Dubertret, and G. French Psoriasis, Psoriasis: Characterization of six different clinical phenotypes. Experimental Dermatolog., 2009. 18(8): p. 712-9.
78. Schon, M.P., Animal models of psoriasis: A critical appraisal. Experimental Dermatology, 2008. 17(8): p. 703-12.
79. Christensen, T.E., K.P. Callis, J. Papenfuss, M.S. Hoffman, C.B. Hansen, B. Wong, J.M. Panko, and G.G. Krueger, Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque psoriasis, and their associated phenotypes. Journal of Investigative Dermatolog., 2006. 126(11): p. 2397-403.
80. Youn, J.I., B.S. Park, S.B. Park, S.D. Kim, and D.H. Suh, Characterization of early and late onset psoriasis in the korean population. The Journal of dermatology, 1999. 26(10):p. 647-52.
81. Henseler, T. and E. Christophers, Psoriasis of early and late onset -characterization of 2 types of psoriasis-vulgaris. J. Am. Acad. Dermatol., 1985. 13(3): p. 450-6.
82. Kwon, H.H., I.H. Kwon, and J.I. Youn, Clinical study of psoriasis occurring over the age of 60 years: Is elderly-onset psoriasis a distinct subtype? International Journal of Dermatology, 2012. 51(1): p. 53-8.
83. Uva, L., D. Miguel, C. Pinheiro, J. Antunes, D. Cruz, J. Ferreira, and P. Filipe, Mechanisms of action of topical corticosteroids in psoriasis. Int. J. Endocrinol., 2012. 2012: p. 561018.
84. Bowcock, A.M. and J.G. Krueger, Getting under the skin: The immunogenetics of psoriasis (vol 5, pg 699, 2005). Nature Reviews Immunolog., 2005. 5(10): p. 826-.
85. Schon, M.P. and W.H. Boehncke, Psoriasis. N. Engl. J. Med., 2005. 352(18): p. 1899-912.
86. Hsu, S., K.A. Papp, M.G. Lebwohl, J. Bagel, A. Blauvelt, K.C. Duffin, J. Crowley, L.F. Eichenfield, S.R. Feldman, D.F. Fiorentino, J.M. Gelfand, A.B. Gottlieb, C. Jacobsen, R.E. Kalb, A. Kavanaugh, N.J. Korman, G.G. Krueger, M.A. Michelon, W. Morison, C.T. Ritchlin, L.S. Gold, S.P. Stone, B.E. Strober, A.S. Van Voorhees, S.C. Weiss, K. Wanat and B.F. Bebo, Consensus guidelines for the management of plaque psoriasis. Arch. Dermatol., 2012. 148(1): p. 95-102.
87. Gowda, S., O.M. Goldblum, W.V. McCall, and S.R. Feldman, Factors affecting sleep quality in patients with psoriasis. J. Am. Acad. Dermatol., 2010. 63(1): p. 114-23.
88. Steele, J.A., C. Choi, and P.C. Kwong, Topical tacrolimus in the treatment of inverse psoriasis in children. J. Am. Acad. Dermatol., 2005. 53(4): p. 713-6.
89. Ko, H.C., S.W. Jwa, M. Song, M.B. Kim, and K.S. Kwon, Clinical course of guttate psoriasis: Long-term follow-up study. Journal of Dermatolog., 2010. 37(10): p. 894-9.
90. Martin, B.A., R.J.G. Chalmers, and N.R. Telfer, How great is the risk of further psoriasis following a single episode of acute guttate psoriasis? Arch. Dermatol., 1996. 132(6): p. 717-8.
91. Rosenbach, M., S. Hsu, N.J. Korman, M.G. Lebwohl, M. Young, B.E. Bebo, Jr., and A.S. Van Voorhees, Treatment of erythrodermic psoriasis: From the medical board of the national psoriasis foundation. J. Am. Acad. Dermatol., 2010. 62(4): p. 655-62.
92. Boyd, A.S. and A. Menter, Erythrodermic psoriasis -precipitating factors, course, and prognosis in 50 patients. J. Am. Acad. Dermatol., 1989. 21(5): p. 985-91.
93. Green, M.S., J.H. Prystowsky, S.R. Cohen, J.I. Cohen, and M.G. Lebwohl, Infectious complications of erythrodermic psoriasis. J. Am. Acad. Dermatol., 1996. 34(5): p. 911-4.
94. Nanda, A., S. Kaur, I. Kaur, and B. Kumar, Childhood psoriasis -an epidemiologic survey of 112 patients. Pediatric Dermatolog., 1990. 7(1): p. 19-21.
95. Raychaudhuri, S.P. and J. Gross, A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatric Dermatology, 2000. 17(3): p. 174-8.
96. Morris, A., M. Rogers, G. Fischer, and K. Williams, Childhood psoriasis: A clinical review of 1262 cases. Pediatric Dermatolog., 2001. 18(3): p. 188-98.
97. Benoit, S., A. Toksoy, E.B. Brocker, R. Gillitzer, and M. Goebeler, Treatment of recalcitrant pustular psoriasis with infliximab: Effective reduction of chemokine expression. British Journal of Dermatolog., 2004. 150(5): p. 1009-12.
98. Menter, A., A. Gottlieb, S.R. Feldman, A.S. Van Voorhees, C.L. Leonardi, K.B. Gordon, M. Lebwohl, J.Y.M. Koo, C.A. Elmets, N.J. Korman, K.R. Beutner, and R. Bhushan, Guidelines of care for the management of psoriasis and psoriatic arthritis section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J. Am. Acad. Dermatol., 2008. 58(5): p. 826-50.
99. Gottlieb, A., N.J. Korman, K.B. Gordon, S.R. Feldman, M. Lebwohl, J.Y.M. Koo, A.S. Van Voorhees, C.A.K. Elmets, C.L. Leonardi, K.R. Beutner, R. Bhushan, and A. Menter, Guidelines of care for the management of psoriasis and psoriatic arthritis section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J. Am. Acad. Dermatol., 2008. 58(5): p. 851-64.
100. Alamanos, Y., P.V. Voulgari, and A.A. Drosos, Incidence and prevalence of psoriatic arthritis: A systematic review. Journal of Rheumatolog., 2008. 35(7): p. 1354-8.
101. Rahman, M., K. Alam, M.Z. Ahmad, G. Gupta, M. Afzal, S. Akhter, I. Kazmi, Jyoti, F.J. Ahmad, and F. Anwar, Classical to current approach for treatment of psoriasis: A review. Endocrine, metabolic and immune disorders drug targets, 2012. 12(3): p. 287-302.
102. Patel, M., A. Day, R.B. Warren, and A. Menter, Emerging therapies for the treatment of psoriasis. Dermatol. Ther., (Heidelb), 2012. 2(1): p. 16.
103. Menter, A., N.J. Korman, C.A. Elmets, S.R. Feldman, J.M. Gelfand, K.B. Gordon, A. Gottlieb, J.Y.M. Koo, M. Lebwohl, H.W. Lim, A.S. Van Voorhees, K.R. Beutner, and R. Bhushan, Guidelines of care for the management of psoriasis and psoriatic arthritis section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J. Am. Acad. Dermatol., 2009. 60(4): p. 643-59.
104. Menter, A., N.J. Korman, C.A. Elmets, S.R. Feldman, J.M. Gelfand, K.B. Gordon, A. Gottlieb, J.Y.M. Koo, M. Lebwohl, C.L. Leonardi, H.W. Lim, A.S. Van Voorhees, K.R. Beutner, C. Ryan, R. Bhushan, and G. American Academy of Dermatology Work, Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J. Am. Acad. Dermatol., 2011. 65(1): p. 137-74.
105. Lebwohl, M., The role of salicylic acid in the treatment of psoriasis. International Journal of Dermatolog., 1999. 38(1): p. 16-24.
106. Cornell, R.C. and R.B. Stoughton, Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch. Dermatol., 1985. 121(1): p. 63-7.
107. Tauscher, A.E., A.B. Fleischer, K.C. Phelps, and S.R. Feldman, Psoriasis and pregnancy. Journal of Cutaneous Medicine and Surger., 2002. 6(6): p. 561-70.
108. Bae, Y.S.C., A.S. Van Voorhees, S. Hsu, N.J. Korman, M.G. Lebwohl, M. Young, B. Bebo, A.B. Kimball, and F. Natl Psoriasis, Review of treatment options for psoriasis in pregnant or lactating women: From the medical board of the national psoriasis foundation. J. Am. Acad. Dermatol., 2012. 67(3): p. 459-77.
109. Morimoto, S. and Y. Kumahara, A patient with psoriasis cured by 1 alphahydroxyvitamin d3. Medical journal of Osaka University, 1985. 35(3-4): p. 51-4.
110. Ricketts, J.R., M.J. Rothe, and J.M. Grant-Kels, Nutrition and psoriasis. Clinics in Dermatolog., 2010. 28(6): p. 615-26.
111. Reuter, J., I. Merfort, and C.M. Schempp, Botanicals in dermatology an evidence-based review. Am. J. Clin. Dermatol., 2010. 11(4): p. 247-67.
112. McGill, A., A. Frank, N. Emmett, S.N. Leech, D.M. Turnbull, M.A. Birch-Machin, and N.J. Reynolds, The antipsoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. Faseb. Journa., 2005. 19(3): p. 1012-40.
113. Vogler, B.K. and E. Ernst, Aloe vera: A systematic review of its clinical effectiveness. British Journal of General Practic., 1999. 49(447): p. 823-8.
114. Christaki, E.V. and P.C. Florou-Paneri, Aloe vera: A plant for many uses. Journal of Food Agriculture and Environmen., 2010. 8(2): p. 245-9.
115. Feily, A. and M.R. Namazi, Aloe vera in dermatology: A brief review. Giornale Italiano Di Dermatologia E Venereologia, 2009. 144(1): p. 85-91.
116. Thielitz, A. and H. Gollnick, Topical retinoids in acne vulgaris update on efficacy and safety. Am. J. Clin. Dermatol., 2008. 9(6): p. 369-81.
117. Tsuda, K., K. Yamanaka, H. Kitagawa, T. Akeda, M. Naka, K. Niwa, T. Nakanishi, M. Kakeda, E.C. Gabazza, and H. Mizutani, Calcineurin inhibitors suppress cytokine production from memory t cells and differentiation of naive t cells into cytokineproducing mature t cells. PLoS On., 2012. 7(2): p. e31465.
118. Langley, R.G., A.M. Cherman, and A.K. Gupta, Alefacept: An expert review concerning the treatment of psoriasis. Expert. Opin. Pharmacothe., 2005. 6(13): p. 2327-33.
119. Lapolla, W., B.A. Yentzer, J. Bagel, C.R. Halvorson, and S.R. Feldman, A review of phototherapy protocols for psoriasis treatment. J. Am. Acad. Dermatol., 2011. 64(5): p. 936-49.
120. Matz, H., Phototherapy for psoriasis: What to choose and how to use: Facts and controversies. Clinics in Dermatolog., 2010. 28(1): p. 73-80.
121. Kelly, E.W., Jr. and H. Pinkus, Local application of 8-methoxypsoralen in vitiligo. J. Invest. Dermatol., 1955. 25(6): p. 453-6.
122. Menter, A., N.J. Korman, C.A. Elmets, S.R. Feldman, J.M. Gelfand, K.B. Gordon, A. Gottlieb, J.Y.M. Koo, M. Lebwohl, H.W. Lim, A.S. Van Voorhees, K.R. Beutner, and R. Bhushan, Guidelines of care for the management of psoriasis and psoriatic arthritis section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J. Am. Acad. Dermatol., 2010. 62(1): p. 114-35.
123. Honigsmann, H., Phototherapy for psoriasis. Clin. Exp. Dermatol., 2001. 26(4): p. 343-50.
124. Herrier, R.N., Advances in the treatment of moderate-to-severe plaque psoriasis. American Journal of Health-System Pharmac., 2011. 68(9): p. 795-806.
125. Chan, E.S.L. and B.N. Cronstein, Methotrexate-how does it really work? Nature Reviews Rheumatology, 2010. 6(3): p. 175-8.
126. Shen, S., T. O'Brien, L.M. Yap, H.M. Prince, and C.J. McCormack, The use of methotrexate in dermatology: A review. Australasian Journal of Dermatolog., 2012. 53(1): p. 1-18.
127. Wang, Y.C. and E.P.I. Chiang, Low-dose methotrexate inhibits methionine sadenosyltransferase in vitro and in vivo. Mol. Med., 2012. 18(3): p. 423-32.
128. Nesher, G., T.L. Moore, and R.W. Dorner, Invitro effects of methotrexate on peripheral-blood monocytes -modulation by folinic acid and s-adenosylmethionine. Ann. Rheum. Dis., 1991. 50(9): p. 637-41.
129. Rosenberg, P., H. Urwitz, A. Johannesson, A.-M. Ros, J. Lindholm, N. Kinnman, and R. Hultcrantz, Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. Journal of Hepatolog., 2007. 46(6): p. 1111-8.
130. Zumtobel, U., H.P. Schwarze, M. Favre, A. Taieb, and M. Delaunay, Widespread cutaneous carcinomas associated with human papillomaviruses 5, 14 and 20 after introduction of methotrexate in two long-term puva-treated patients. Dermatolog., 2001. 202(2): p. 127-30.
131. Makol, A., K. Wright, and S. Amin, Rheumatoid arthritis and pregnancy safety considerations in pharmacological management. Drug., 2011. 71(15): p. 1973-87.
132. Watanabe, K., K. Takase, S. Ohno, H. Ideguchi, A. Nozaki, and Y. Ishigatsubo, Reactivation of hepatitis b virus in a hepatitis b surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. Modern Rheumatolog., 2012. 22(3): p. 470-3.
133. Deeming, G.M.J., J. Collingwood, and M.N. Pemberton, Methotrexate and oral ulceration. Br. Dent. J., 2005. 198(2): p. 83-5.
134. Pearce, H.P. and B.B. Wilson, Erosion of psoriatic plaques: An early sign of methotrexate toxicity. J. Am. Acad. Dermatol., 1996. 35(5): p. 835-8.
135. Wollina, U., K. Stander, and U. Barta, Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis -short-and long-term toxicity in 104 patients. Clinical Rheumatolog., 2001. 20(6): p. 406-10.
136. Chen, Y.J., Y.T. Chang, J.L. Shen, T.T. Chen, C.B. Wang, C.M. Chen, and C.Y. Wu, Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: A nationwide cohort study. Arthritis and Rheumatis., 2012. 64(6): p. 1879-87.
137. Prodanowich, S., F.C. Ma, J.R. Taylor, C. Pezon, T. Fasihi, and R.S. Kirsner, Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J. Am. Acad. Dermatol., 2005. 52(2): p. 262-7.
138. Choi, H.K., M.A. Hernan, J.D. Seeger, J.M. Robins, and F. Wolfe, Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lance., 2002. 359(9313): p. 1173-7.
139. Bangert, C.A. and M.I. Costner, Methotrexate in dermatology. Dermatol. Ther., 2007. 20(4): p. 216-28.
140. Mueller, W. and B. Herrmann, Cyclosporin a for psoriasis. New England Journal of Medicin., 1979. 301(10): p. 555-.
141. Dehesa, L., A. Abuchar, A. Nuno-Gonzalez, M. Vitiello, and F.A. Kerdel, The use of cyclosporine in dermatology. Journal of Drugs in Dermatolog., 2012. 11(8): p. 979-87.
142. Amor, K.T., C. Ryan, and A. Menter, The use of cyclosporine in dermatology: Part i. J. Am. Acad. Dermatol., 2010. 63(6): p. 925-46.
143. Mrowietz, U., New findings on the mode of action of cyclosporinein psoriasis -a review with guidelines for therapy. Hautarz., 1993. 44(6): p. 353-60.
144. Ockenfels, H.M., G. Nussbaum, B. Schneck, S.N. Wagner, E. Haen, and M. Goos, The effect of cyclosporin a and fk 506 on the camp content in psoriatic keratinocytes. Skin Pharmacolog., 1996. 9(4): p. 281-8.
145. Cho, M.L., C.S. Cho, S.Y. Min, S.H. Kim, S.S. Lee, W.U. Kim, D.J. Min, J.K. Min, J.H. Youn, S.Y. Hwang, S.H. Park, and H.Y. Kim, Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts. Arthritis and Rheumatis., 2002. 46(5): p. 1202-9.
146. Ryan, C., K.T. Amor, and A. Menter, The use of cyclosporine in dermatology: Part ii. J. Am. Acad. Dermatol., 2010. 63(6): p. 949-72.
147. Uhlenhake, E.E. and D.A. Mehregan, Managing psoriasis: What's best for your patient? Journal of Family Practice, 2012. 61(7): p. 402-+.
148. Chia, T.Y., M.A. Sattar, M.H. Abdulla, and E.J. Johns, The effect of cyclosporine-a on the renal vascular response to ang ii and adrenegic agonist in sprague-dawley rat. Healthme., 2011. 5(6): p. 1857-67.
149. Taler, S.J., S.C. Textor, V.J. Canzanello, and L. Schwartz, Cyclosporin-induced hypertension -incidence, pathogenesis and management. Drug Safet., 1999. 20(5): p. 437-49.
150. Muellenhoff, M.W. and J.Y. Koo, Cyclosporine and skin cancer: An international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology. Journal of Dermatological Treatmen., 2012. 23(4): p. 290-304.
151. Rosmarin, D.M., M. Lebwohl, B.E. Elewski, and A.B. Gottlieb, Cyclosporine and psoriasis: 2008 national psoriasis foundation consensus conference. J Am Acad Dermatol, 2010. 62(5): p. 838-53.
152. Mahe, E., Cyclosporine in childhood psoriasis. Arch. Dermatol., 2001. 137(11): p. 1532-3.
153. de Jager, M.E.A., E. de Jong, P.C.M. van de Kerkhof, and M.M.B. Seyger, Efficacy and safety of treatments for childhood psoriasis: A systematic literature review. J. Am. Acad. Dermatol., 2010. 62(6): p. 1013-30.
154. Niu, X.W., W. Cao, H.Q. Ma, J. Feng, X.M. Li, and X.H. Zhang, Acitretin exerted a greater influence on t-helper (th)1 and th17 than on th2 cells in treatment of psoriasis vulgaris. Journal of Dermatolog., 2012. 39(11): p. 916-21.
155. Buccheri, L., B.R. Katchen, A.J. Karter, and S.R. Cohen, Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch. Dermatol., 1997. 133(6): p. 711-5.
156. Ayroldi, E., A. Bastianelli, L. Cannarile, M.G. Petrillo, D.V. Delfino, and A. Fierabracci, A pathogenetic approach to autoimmune skin disease therapy: Psoriasis and biological drugs, unresolved issues, and future directions. Curr. Pharm. Des., 2011. 17(29): p. 3176-90.
157. Menter, A. and C.E. Griffiths, Current and future management of psoriasis. Lance., 2007. 370(9583): p. 272-84.
158. Nickoloff, B.J., The cytokine network in psoriasis. Arch. Dermatol., 1991. 127(6): p. 871-84.
159. Nickoloff, B.J., Cracking the cytokine code in psoriasis. Nat. Med., 2007. 13(3): p. 242-4.
160. Rustin, M.H.A., Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: Review of current data. British Journal of Dermatology, 2012. 167: p. 3-11.
161. Benucci, M., G. Saviola, M. Manfredi, P. Sarzi-Puttini, and F. Atzeni, Tumor necrosis factors blocking agents: Analogies and differences. Acta. Biomed., 2012. 83(1): p. 72-80.
162. Pariser, D.M., C.L. Leonardi, K. Gordon, A.B. Gottlieb, S. Tyring, K.A. Papp, J. Li, and S.W. Baumgartner, Integrated safety analysis: Short-and long-term safety profiles of etanercept in patients with psoriasis. J. Am. Acad. Dermatol., 2012. 67(2): p. 245-56.
163. Papp, K.A., J. DeKoven, L. Parsons, S. Pirzada, M. Robern, L. Robertson, and J.K.L. Tan, Biologic therapy in psoriasis: Perspectives on associated risks and patient management. Journal of Cutaneous Medicine and Surger., 2012. 16(3): p. 153-68.
164. Calabrese, L.H., N.N. Zein, and D. Vassilopoulos, Hepatitis b virus (hbv) reactivation with immunosuppressive therapy in rheumatic diseases: Assessment and preventive strategies. Ann. Rheum. Dis., 2006. 65(8): p. 983-9.
165. Anderson, L.A., S. Gadalla, L.M. Morton, O. Landgren, R. Pfeiffer, J.L. Warren, S.I. Berndt, W. Ricker, R. Parsons, and E.A. Engels, Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. International Journal of Cance., 2009. 125(2): p. 398-405.
166. Naldi, L., Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: Facts and controversies. Clinics in Dermatolog., 2010. 28(1): p. 88-92.
167. Valdimarsson, H., R.H. Thorleifsdottir, S.L. Sigurdardottir, J.E. Gudjonsson, and A. Johnston, Psoriasis -as an autoimmune disease caused by molecular mimicry. Trends in Immunolog., 2009. 30(10): p. 494-501.
168. Baker, B.S., A. Powles, and L. Fry, Peptidoglycan: A major aetiological factor for psoriasis? Trends in Immunology, 2006. 27(12): p. 545-51.
169. Sagi, L. and H. Trau, The koebner phenomenon. Clinics in Dermatolog., 2011. 29(2): p. 231-6.
170. Basavaraj, K.H., N.M. Ashok, R. Rashmi, and T.K. Praveen, The role of drugs in the induction and/or exacerbation of psoriasis. International Journal of Dermatolog., 2010. 49(12): p. 1351-61.
171. Li, W.Q., J.L. Han, H.K. Choi, and A.A. Qureshi, Smoking and risk of incident psoriasis among women and men in the united states: A combined analysis. American Journal of Epidemiolog., 2012. 175(5): p. 402-13.
172. Kwatra, S.G., Alcohol intake and risk of psoriasis: Smoking as a confounding factor. Arch. Dermatol., 2011. 147(3): p. 358; author reply -9.
173. Duffin, K.C., J. Woodcock, and G.G. Krueger, Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association. Dermatologic Therapy, 23(2): p. 101-13.
174. Stuart, P.E., R.P. Nair, E. Ellinghaus, J. Ding, T. Tejasvi, J.E. Gudjonsson, Y. Li, S. Weidinger, B. Eberlein, C. Gieger, H.E. Wichmann, M. Kunz, R. Ike, G.G. Krueger, A.M. Bowcock, U. Mrowietz, H.W. Lim, J.J. Voorhees, G.R. Abecasis, M. Weichenthal, A. Franke, P. Rahman, D.D. Gladman, and J.T. Elder, Genome-wide association analysis identifies three psoriasis susceptibility loci. Nature Genetics, 42(11): p. 1000-U125.
175. Schon, M.P., Animal models of psoriasis -what can we learn from them? Journal of Investigative Dermatology, 1999. 112(4): p. 405-10.
176. Wagner, E.F., H.B. Schonthaler, J. Guinea-Viniegra, and E. Tschachler, Psoriasis: What we have learned from mouse models. Nature Reviews Rheumatology, 6(12): p. 704-14.
177. WroneSmith, T. and B.J. Nickoloff, Dermal injection of immunocytes induces psoriasis. Journal of Clinical Investigatio., 1996. 98(8): p. 1878-87.
178. Tsoi, L.C., S.L. Spain, J. Knight, E. Ellinghaus, P.E. Stuart, F. Capon, J. Ding, Y. Li, T. Tejasvi, J.E. Gudjonsson, H.M. Kang, M.H. Allen, R. McManus, G. Novelli, L. Samuelsson, J. Schalkwijk, M. Stahle, A.D. Burden, C.H. Smith, M.J. Cork, X. Estivill, A.M. Bowcock, G.G. Krueger, W. Weger, J. Worthington, R. Tazi-Ahnini, F.O. Nestle, A. Hayday, P. Hoffmann, J. Winkelmann, C. Wijmenga, C. Langford, S. Edkins, R. Andrews, H. Blackburn, A. Strange, G. Band, R.D. Pearson, D. Vukcevic, C.C. Spencer, P. Deloukas, U. Mrowietz, S. Schreiber, S. Weidinger, S. Koks, K. Kingo, T. Esko, A. Metspalu, H.W. Lim, J.J. Voorhees, M. Weichenthal, H.E. Wichmann, V. Chandran, C.F. Rosen, P. Rahman, D.D. Gladman, C.E. Griffiths, A. Reis, J. Kere, P. Collaborative Association Study of, K.C. Duffin, C. Helms, D. Goldgar, Y. Li, J. Paschall, M.J. Malloy, C.R. Pullinger, J.P. Kane, J. Gardner, A. Perlmutter, A. Miner, B.J. Feng, R. Hiremagalore, R.W. Ike, E. Christophers, T. Henseler, A. Ruether, S.J. Schrodi, S. Prahalad, S.L. Guthery, J. Fischer, W. Liao, P. Kwok, A. Menter, G.M. Lathrop, C. Wise, A.B. Begovich, C. Genetic Analysis of Psoriasis, A. Onoufriadis, M.E. Weale, A. Hofer, W. Salmhofer, P. Wolf, K. Kainu, U. Saarialho-Kere, S. Suomela, P. Badorf, U. Huffmeier, W. Kurrat, W. Kuster, J. Lascorz, R. Mossner, F. Schurmeier-Horst, M. Stander, H. Traupe, J.G. Bergboer, M. Heijer, P.C. van de Kerkhof, P.L. Zeeuwen, L. Barnes, L.E. Campbell, C. Cusack, C. Coleman, J. Conroy, S. Ennis, O. Fitzgerald, P. Gallagher, A.D. Irvine, B. Kirby, T. Markham, W.H. McLean, J. McPartlin, S.F. Rogers, A.W. Ryan, A. Zawirska, E. Giardina, T. Lepre, C. Perricone, G. Martin-Ezquerra, R.M. Pujol, E. Riveira-Munoz, A. Inerot, A.T. Naluai, L. Mallbris, K. Wolk, J. Leman, A. Barton, R.B. Warren, H.S. Young, I. Ricano-Ponce, G. Trynka, E. Psoriasis Association Genetics, F.J. Pellett, A. Henschel, M. Aurand, B. Bebo, C. Gieger, T. Illig, S. Moebus, K.H. Jockel, R. Erbel, C. Wellcome Trust Case Control, P. Donnelly, L. Peltonen, J.M. Blackwell, E. Bramon, M.A. Brown, J.P. Casas, A. Corvin, N. Craddock, A. Duncanson, J. Jankowski, H.S. Markus, C.G. Mathew, M.I. McCarthy, C.N. Palmer, R. Plomin, A. Rautanen, S.J. Sawcer, N. Samani, A.C. Viswanathan, N.W. Wood, C. Bellenguez, C. Freeman, G. Hellenthal, E. Giannoulatou, M. Pirinen, Z. Su, S.E. Hunt, R. Gwilliam, S.J. Bumpstead, S. Dronov, M. Gillman, E. Gray, N. Hammond, A. Jayakumar, O.T. McCann, J. Liddle, M.L. Perez, S.C. Potter, R. Ravindrarajah, M. Ricketts, M. Waller, P. Weston, S. Widaa, P. Whittaker, R.P. Nair, A. Franke, J.N. Barker, G.R. Abecasis, J.T. Elder and R.C. Trembath, Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet, 2012. 44(12): p. 1341-8.
179. Tiilikainen, A., A. Lassus, J. Karvonen, P. Vartiainen, and M. Julin, Psoriasis and hlacw6. British Journal of Dermatolog., 1980. 102(2): p. 179-84.
180. Liu, Y., C. Helms, W. Liao, L.C. Zaba, S. Duan, J. Gardner, C. Wise, A. Miner, M.J. Malloy, C.R. Pullinger, J.P. Kane, S. Saccone, J. Worthington, I. Bruce, P.Y. Kwok, A. Menter, J. Krueger, A. Barton, N.L. Saccone, and A.M. Bowcock, A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. Plos Genetics, 2008. 4(4).
181. Roberson, E.D. and A.M. Bowcock, Psoriasis genetics: Breaking the barrier. Trends Gene., 2010. 26(9): p. 415-23.
182. Nair, R.P., K.C. Duffin, C. Helms, J. Ding, P.E. Stuart, D. Goldgar, J.E. Gudjonsson, Y. Li, T. Tejasvi, B.-J. Feng, A. Ruether, S. Schreiber, M. Weichenthal, D. Gladman, P. Rahman, S.J. Schrodi, S. Prahalad, S.L. Guthery, J. Fischer, W. Liao, P.-Y. Kwok, A. Menter, G.M. Lathrop, C. Awise, A.B. Begovich, J.J. Voorhees, J.T. Elder, G.G. Krueger, A.M. Bowcock, G.R. Abecasis and P. Collaborative Assoc Study, Genome-wide scan reveals association of psoriasis with il-23 and nf-kappa b pathways. Nature Genetic., 2009. 41(2): p. 199-204.
183. Elder, J.T., A.T. Bruce, J.E. Gudjonsson, A. Johnston, P.E. Stuart, T. Tejasvi, J.J. Voorhees, G.R. Abecasis, and R.P. Nair, Molecular dissection of psoriasis: Integrating genetics and biology. Journal of Investigative Dermatolog., 2010. 130(5): p. 1213-26.
184. Capon, F., A.D. Burden, R.C. Trembath, and J.N. Barker, Psoriasis and other complex trait dermatoses: From loci to functional pathways. Journal of Investigative Dermatolog., 2012. 132(3): p. 915-22.
185. Bowcock, A.M., W. Shannon, F.H. Du, J. Duncan, K. Cao, K. Aftergut, J. Catier, M.A. Fernandez-Vina, and A. Menter, Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum. Mol. Genet., 2001. 10(17): p. 1793-805.
186. Delpire, E. and D.B. Mount, Human and murine phenotypes associated with defects in cation-chloride cotransport. Annual Review of Physiology, 2002. 64: p. 803-43.
187. Huffmeier, U., J. Lascorz, H. Traupe, B. Bohm, F. Schurmeier-Horst, M. Stander, R. Kelsch, C. Baumann, W. Kuster, H. Burkhardt, and A. Reis, Systematic linkage disequilibrium analysis of slc12a8 at psors5 confirms a role in susceptibility to psoriasis vulgaris. Journal of Investigative Dermatolog., 2005. 125(5): p. 906-12.
188. Tschachler, E., Psoriasis: The epidermal component. Clinics in Dermatolog., 2007. 25(6): p. 589-95.
189. Alappatt, C., C.A. Johnson, K.L. Clay, and J.B. Travers, Acute keratinocyte damage stimulates platelet-activating factor production. Archives of Dermatological Researc., 2000. 292(5): p. 256-9.
190. Steinhoff, M., T. Brzoska, and T.A. Luger, Keratinocytes in epidermal immune responses. Current opinion in allergy and clinical immunolog., 2001. 1(5): p. 469-76.
191. Grone, A., Keratinocytes and cytokines. Veterinary Immunology and Immunopathology, 2002. 88(1-2): p. 1-12.
192. Takashima, A., H. Matsue, P.R. Bergstresser, and K. Ariizumi, Interleukin-7-dependent interaction of dendritic epidermal t-cells with keratinocytes. Journal of Investigative Dermatolog., 1995. 105(1): p. S50-S3.
193. Devos, S., M. Brach, A. Budnik, M. Grewe, F. Herrmann, and J. Krutmann, Posttranscriptional regulation of interleukin-6 gene-expression in human keratinocytes by ultraviolet-b radiation. Journal of Investigative Dermatolog., 1994. 103(1): p. 92-6.
194. Williams, I.R., E.A. Rawson, L. Manning, T. Karaoli, B.E. Rich, and T.S. Kupper, Il-7 overexpression in transgenic mouse keratinocytes causes a lymphoproliferative skin disease dominated by intermediate tcr cells -evidence for a hierarchy in il-7 responsiveness among cutaneous t cells. Journal of Immunolog., 1997. 159(6): p. 3044-56.
195. Ullrich, S.E., Mechanism involved in the systemic suppression of antigen-presenting cell-function by uv irradiation -keratinocyte-derived il-10 modulates antigen-presenting cell-function of splenic adherent cells. Journal of Immunology, 1994. 152(7):p. 3410-6.
196. Yawalkar, N., F. Egli, C.U. Brand, W.J. Pichler, and L.R. Braathen, Antigen-presenting cells and keratinocytes express interleukin-12 in allergic contact dermatitis. Contact Dermatiti., 2000. 42(1): p. 18-22.
197. Blumberg, H., D. Conklin, W.F. Xu, A. Grossmann, T. Brender, S. Carollo, M. Eagan, D. Foster, B.A. Haldeman, A. Hammond, H. Haugen, L. Jelinek, J.D. Kelly, K. Madden, M.F. Maurer, J. Parrish-Novak, D. Prunkard, S. Sexson, C. Sprecher, K. Waggie, J. West, T.E. Whitmore, L. Yao, M.K. Kuechle, B.A. Dale and Y.A. Chandrasekher, Interleukin 20: Discovery, receptor identification, and role in epidermal function. Cel., 2001. 104(1): p. 9-19.
198. Mustoe, T.A. and A. Gurjala, The role of the epidermis and the mechanism of action of occlusive dressings in scarring. Wound Repair and Regeneration, 2011. 19: p. S16-S21.
199. Freedberg, I.M., M. Tomic-Canic, M. Komine, and M. Blumenberg, Keratins and the keratinocyte activation cycle. Journal of Investigative Dermatolog., 2001. 116(5): p. 633-40.
200. Pei, Y., L.A. Barber, R.C. Murphy, C.A. Johnson, S.W. Kelley, L.C. Dy, R.H. Fertel, T.M. Nguyen, D.A. Williams, and J.B. Travers, Activation of the epidermal platelet-activating factor receptor results in cytokine and cyclooxygenase-2 biosynthesis. Journal of Immunolog., 1998. 161(4): p. 1954-61.
201. Zhang, Q., H. Seltmann, C.C. Zouboulis, and J.B. Travers, Activation of platelet-activating factor receptor in sz95 sebocytes results in inflammatory cytokine and prostaglandin e-2 production. Experimental dermatolog., 2006. 15(10): p. 769-74.
202. Travers, J.B., J.C. Huff, M. Rolapleszczynski, E.W. Gelfand, J.G. Morelli, and R.C. Murphy, Identification of functional platelet-activating-factor receptors on human keratinocytes. Journal of Investigative Dermatolog., 1995. 105(6): p. 816-23.
203. Muller, G., J. Saloga, T. Germann, I. Bellinghausen, M. Mohamadzadeh, J. Knop, and A.H. Enk, Identification and induction of human keratinocyte-derived il-12. Journal of Clinical Investigatio., 1994. 94(5): p. 1799-805.
204. Zenz, R., R. Eferl, L. Kenner, L. Florin, L. Hummerich, D. Mehic, H. Scheuch, P. Angel, E. Tschachler, and E.F. Wagner, Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of jun proteins (vol 437, pg 369, 2005). Natur., 2006. 440(7084): p. 708-.
205. Zhang, X.-J., W. Huang, S. Yang, L.-D. Sun, F.-Y. Zhang, Q.-X. Zhu, F.-R. Zhang, C. Zhang, W.-H. Du, X.-M. Pu, H. Li, F.-L. Xiao, Z.-X. Wang, Y. Cui, F. Hao, J. Zheng, X.-Q. Yang, H. Cheng, C.-D. He, X.-M. Liu, L.-M. Xu, H.-F. Zheng, S.-M. Zhang, J. Z. Zhang, H.-Y. Wang, Y.-L. Cheng, B.-H. Ji, Q.-Y. Fang, Y.-Z. Li, F.-S. Zhou, J.-W. Han, C. Quan, B. Chen, J.-L. Liu, D. Li, L. Fan, A.-P. Zhang, S.-X. Liu, C.-J. Yang, P. G. Wang, W.-M. Zhou, G.-S. Lin, W.-D. Wu, X. Fan, M. Gao, B.-Q. Yang, W.-S. Lu, Z. Zhang, K.-J. Zhu, S.-K. Shen, M. Li, X.-Y. Zhang, T.-T. Cao, W. Ren, X. Zhang, J. He, X.-F. Tang, S. Lu, J.-Q. Yang, L. Zhang, D.-N. Wang, F. Yuan, X.-Y. Yin, H.-J. Huang, H.-F. Wang, X.-Y. Lin and J.-J. Liu, Psoriasis genome-wide association study identifies susceptibility variants within lce gene cluster at 1q21. Nature Genetic., 2009. 41(2): p. 205-10.
206. Chen, H., T.K.L. Toh, I. Szeverenyi, R.T.H. Ong, C.T.S. Theng, W.H.I. McLean, M. Seielstad, and E.B. Lane, Association of skin barrier genes within the psors4 locus is enriched in singaporean chinese with early-onset psoriasis. Journal of Investigative Dermatolog., 2009. 129(3): p. 606-14.
207. Docampo, E., E. Giardina, E. Riveira-Munoz, R. de Cid, G. Escaramis, C. Perricone, J.L. Fernandez-Sueiro, J. Maymo, M.A. Gonzalez-Gay, F.J. Blanco, U. Hueffmeier, M. Pilar Lisbona, J. Martin, A. Carracedo, A. Reis, R. Rabionet, G. Novelli, and X. Estivill, Deletion of lce3c and lce3b is a susceptibility factor for psoriatic arthritis: A study in spanish and italian populations and meta-analysis. Arthritis and Rheumatism, 63(7): p. 1860-5.
208. Docampo, E., R. Rabionet, E. Riveira-Munoz, G. Escaramis, A. Julia, S. Marsal, J. Ezequiel Martin, M. Angel Gonzalez-Gay, A. Balsa, E. Raya, J. Martin, and X. Estivill, Deletion of the late cornified envelope genes, lce3c and lce3b, is associated with rheumatoid arthritis. Arthritis and Rheumatism, 62(5): p. 1246-51.
209. Yoshida, Y., K. Morita, A. Mizoguchi, C. Ide, and Y. Miyachi, Altered expression of occludin and tight junction formation in psoriasis. Archives of Dermatological Researc., 2001. 293(5): p. 239-44.
210. Presland, R.B., Function of filaggrin and caspase-14 in formation and maintenance of the epithelial barrier. Dermatologica Sinic., 2009. 27(1): p. 1-14.
211. de Cid, R., E. Riveira-Munoz, P.L.J.M. Zeeuwen, J. Robarge, W. Liao, E.N. Dannhauser, E. Giardina, P.E. Stuart, R. Nair, C. Helms, G. Escaramis, E. Ballana, G. Martin-Ezquerra, M. den Heijer, M. Kamsteeg, I. Joosten, E.E. Eichler, C. Lazaro, R.M. Pujol, L. Armengol, G. Abecasis, J.T. Elder, G. Novelli, J.A.L. Armour, P.-Y. Kwok, A. Bowcock, J. Schalkwijk and X. Estivill, Deletion of the late cornified envelope lce3b and lce3c genes as a susceptibility factor for psoriasis. Nature Genetic., 2009. 41(2): p. 211-5.
212. Mattozzi, C., A.G. Richetta, C. Cantisani, L. Macaluso, and S. Calvieri, Psoriasis: New insight about pathogenesis, role of barrier organ integrity, nlr/caterpiller family genes and microbial flora. Journal of Dermatolog., 2012. 39(9): p. 752-60.
213. Schalkwijk, L., E.J. Hollox, U. Huffmeier, P.L. Zeeuwen, R. Palla, J. Lascorz, D.R. Olthuis, P.C.v. de Kerkhoi, H. Traupe, M. den Heijer, A. Reis, and J.A. Armour, Psoriasis is associated with increased beta-defensin genomic copy number. Journal of Investigative Dermatology, 2008. 128: p. S113-S.
214. Harder, J., J. Bartels, E. Christophers, and J.M. Schroder, A peptide antibiotic from human skin. Natur., 1997. 387(6636): p. 861-.
215. Ganz, T., Defensins: Antimicrobial peptides of innate immunity. Nature Reviews Immunolog., 2003. 3(9): p. 710-20.
216. Niyonsaba, F., H. Ushio, I. Nagaoka, K. Okumura, and H. Ogawa, The human betadefensins (-1,-2,-3,-4) and cathelicidin ll-37 induce il-18 secretion through p38 and erk mapk activation in primary human keratinocytes. Journal of Immunolog., 2005. 175(3): p. 1776-84.
217. Karvonen, S.L., T. Korkiamaki, H. Yla-Outinen, M. Nissinen, H. Teerikangas, K. Pummi, J. Karvonen, and J. Peltonen, Psoriasis and altered calcium metabolism: Downregulated capacitative calcium influx and defective calcium-mediated cell signaling in cultured psoriatic keratinocytes. Journal of Investigative Dermatolog., 2000. 114(4): p. 693-700.
218. Bernstein, J.A. and P.J. Didier, Nonhuman primate dermatology: A literature review. Vet Dermato., 2009. 20(3): p. 145-56.
219. Jayo, M.J., M.D. Zanolli, and J.M. Jayo, Psoriatic plaques in macaca-fascicularis. Veterinary Patholog., 1988. 25(4): p. 282-5.
220. Zanolli, M.D., M.J. Jayo, J.M. Jayo, D. Blaine, J. Hall, and J.L. Jorizzo, Evaluation of psoriatic plaques that spontaneously developed in a cynomolgus monkey (macaca fascicularis). Acta dermato-venereologica. Supplementum, 1989. 146: p. 58.
221. Wagner, E.F., H.B. Schonthaler, J. Guinea-Viniegra, and E. Tschachler, Psoriasis: What we have learned from mouse models. Nature Reviews Rheumatolog., 2010. 6(12): p. 704-14.
222. Boehncke, W.-H. and M.P. Schoen, Animal models of psoriasis. Clinics in Dermatolog., 2007. 25(6): p. 596-605.
223. Hirano, T., K. Ishihara, and M. Hibi, Roles of stat3 in mediating the cell growth, differentiation and survival signals relayed through the il-6 family of cytokine receptors. Oncogen., 2000. 19(21): p. 2548-56.
224. Sano, S., K.S. Chan, S. Carbajal, J. Clifford, M. Peavey, K. Kiguchi, S. Itami, B.J. Nickoloff, and J. DiGiovanni, Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nature Medicin., 2005. 11(1): p. 43-9.
225. Eferl, R. and E.F. Wagner, Ap-1: A double-edged sword in tumorigenesis. Nature Reviews Cance., 2003. 3(11): p. 859-68.
226. Mehic, D., L. Bakiri, M. Ghannadan, E.F. Wagner, and E. Tschachler, Fos and jun proteins are specifically expressed during differentiation of human keratinocytes. Journal of Investigative Dermatolog., 2005. 124(1): p. 212-20.
227. Shaulian, E. and M. Karin, Ap-1 as a regulator of cell life and death. Nat. Cell Biol., 2002. 4(5): p. E131-E6.
228. Haider, A.S., J. Duculan, J.A. Whynot, and J.G. Krueger, Increased junb mrna and protein expression in psoriasis vulgaris lesions. Journal of Investigative Dermatolog., 2006. 126(4): p. 912-4.
229. Mombaerts, P., J. Iacomini, R.S. Johnson, K. Herrup, S. Tonegawa, and V.E. Papaioannou, Rag-1-deficient mice have no mature lymphocytes-b and lymphocytes-t. Cel., 1992. 68(5): p. 869-77.
230. Angel, P., A. Szabowski, and M. Schorpp-Kistner, Function and regulation of ap-1 subunits in skin physiology and pathology. Oncogen., 2001. 20(19): p. 2413-23.
231. Zenz, R. and E.F. Wagner, Jun signalling in the epidermis: From developmental defects to psoriasis and skin tumors. International Journal of Biochemistry and Cell Biolog., 2006. 38(7): p. 1043-9.
232. Diamond, I., T. Owolabi, M. Marco, C. Lam, and A. Glick, Conditional gene expression in the epidermis of transgenic mice using the tetracycline-regulated transactivators tta and rta linked to the keratin 5 promoter. Journal of Investigative Dermatolog., 2000. 115(5): p. 788-94.
233. Kuroda, K., A. Sapadin, T. Shoji, R. Fleischmajer, and M. Lebwohl, Altered expression of angiopoietins and tie2 endothelium receptor in psoriasis. Journal of Investigative Dermatolog., 2001. 116(5): p. 713-20.
234. Sato, T.N., Y. Tozawa, U. Deutsch, K. Wolburgbuchholz, Y. Fujiwara, M. Gendronmaguire, T. Gridley, H. Wolburg, W. Risau, and Y. Qin, Distinct roles of the receptor tyrosine kinases tie-1 and tie-2 in blood-vessel formation. Natur., 1995. 376(6535): p. 70-4.
235. Wolfram, J.A., D. Diaconu, D.A. Hatala, J. Rastegar, D.A. Knutsen, A. Lowther, D. Askew, A.C. Gilliam, T.S. McCormick, and N.L. Ward, Keratinocyte but not endothelial cell-specific overexpression of tie2 leads to the development of psoriasis. Am. J. Pathol., 2009. 174(4): p. 1443-58.
236. Wang, Y., H. Gao, C.M. Loyd, W. Fu, D. Diaconu, S. Liu, K.D. Cooper, T.S. McCormick, D.I. Simon, and N.L. Ward, Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. Journal of Investigative Dermatolog., 2012. 132(8): p. 2067-75.
237. Fraki, J.E., R.A. Briggaman, and G.S. Lazarus, Uninvolved skin from psoriatic patients develops signs of involved psoriatic skin after being grafted onto nude-mice. Scienc., 1982. 215(4533): p. 685-7.
238. Menon, G.K. and P.M. Elias, Ultrastructural localization of calcium in psoriatic and normal human epidermis. Arch. Dermatol., 1991. 127(1): p. 57-63.
239. Schweckendiek, W., Treatment of psoriasis vulgaris. Medizinische Monatsschrif., 1959. 13(2): p. 103-4.
240. Gold, R., R.A. Linker, and M. Stangel, Fumaric acid and its esters: An emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clinical Immunolog., 2012. 142(1): p. 44-8.
241. Rostami-Yazdi, M., B. Clement, and U. Mrowietz, Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. Archives of Dermatological Researc., 2010. 302(7): p. 531-8.
242. Hodges, N., A. Anstey, and J. Ingram, Fumaric acid esters for psoriasis: Patient perceptions of an unlicensed medication. J. Am. Acad. Dermatol., 2012. 66(4): p. AB193-AB.
243. Altmeyer, P.J., U. Matthes, F. Pawlak, K. Hoffmann, P.J. Frosch, P. Ruppert, S.W. Wassilew, T. Horn, H.W. Kreysel, G. Lutz, J. Barth, I. Rietzschel, and R.K. Joshi, Antipsoriatic effect of fumaric-acid derivatives -results of a multicenter double-blindstudy in 100 patients. J. Am. Acad. Dermatol., 1994. 30(6): p. 977-81.
244. Brewer, L. and S. Rogers, Fumaric acid esters in the management of severe psoriasis. Clin. Exp. Dermatol., 2007. 32(3): p. 246-9.
245. Hoefnagel, J.J., H.B. Thio, R. Willemze, and J.N.B. Bavinck, Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. British Journal of Dermatolog., 2003. 149(2): p. 363-9.
246. Kolbach, D.N. and C. Nieboer, Fumaric-acid therapy in psoriasis -results and side-effects of 2 years of treatment. J. Am. Acad. Dermatol., 1992. 27(5): p. 769-71.
247. Litjens, N.H.R., J. Burggraaf, E. van Strijen, C. van Gulpen, H. Mattie, R.C. Schoemaker, J.T. van Dissel, H.B. Thio, and P.H. Nibbering, Pharmacokinetics of oral fumarates in healthy subjects. British Journal of Clinical Pharmacolog., 2004. 58(4): p. 429-32.
248. Mrowietz, U., E. Christophers, and P. Altmeyer, Treatment of psoriasis with fumaric acid esters: Results of a prospective multicentre study. British Journal of Dermatolog., 1998. 138(3): p. 456-60.
249. Mrowietz, U., E. Christophers, P. Altmeyer, and C. German Fumaric Acid Ester Consensus, Treatment of severe psoriasis with fumaric acid esters: Scientific background and guidelines for therapeutic use. British Journal of Dermatolog., 1999. 141(3): p. 424-9.
250. Nast, A., I.B. Kopp, M. Augustin, K.-B. Banditt, W.-H. Boehncke, M. Follmann, M. Friedrich, M. Huber, C. Kahl, J. Klaus, J. Koza, I. Kreiselmaier, J. Mohr, U. Mrowietz, H.-M. Ockenfels, H.-D. Orzechowski, J. Prinz, K. Reich, T. Rosenbach, S. Rosumeck, M. Schlaeger, G. Schmid-Ott, M. Sebastian, V. Streit, T. Weberschock, B. Rzany and D. Germany Society for, S3-guidelines for the therapy of psoriasis vulgaris. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology, JDDG, 2006. 4 Suppl 2: p. S1-126.
251. Reich, K., D. Thaci, U. Mrowietz, A. Kamps, M. Neureither, and T. Luger, Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis -a retrospective study (future). Journal Der Deutschen Dermatologischen Gesellschaf., 2009. 7(7): p. 603-10.
252. Rostami-Yazdi, M., B. Clement, T.J. Schmidt, D. Schinor, and U. Mrowietz, Detection of metabolites of fumaric acid esters in human urine: Implications for their mode of action. Journal of Investigative Dermatolog., 2009. 129(1): p. 231-4.
253. Schmidt, M.M. and R. Dringen, Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione. Neurochemistry Internationa., 2010. 57(4): p. 460-7.
254. Nelson, K.C., J.L. Carlson, M.L. Newman, P. Sternberg, D.P. Jones, T.J. Kavanagh, D. Diaz, J.Y. Cai, and M. Wu, Effect of dietary inducer dimethylfumarate on glutathione in cultured human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci., 1999. 40(9): p. 1927-35.
255. Ghoreschi, K., J. Bruck, C. Kellerer, C.S. Deng, H.Y. Peng, O. Rothfuss, R.Z. Hussain, A.R. Gocke, A. Respa, I. Glocova, N. Valtcheva, E. Alexander, S. Feil, R. Feil, K. Schulze-Osthoff, R.A. Rupec, A.E. Lovett-Racke, R. Dringen, M.K. Racke, and M. Rocken, Fumarates improve psoriasis and multiple sclerosis by inducing type ii dendritic cells. Journal of Experimental Medicin., 2011. 208(11): p. 2291-303.
256. Thio, H.B., T.P.L. Zomerdijk, C. Oudshoorn, J. Kempenaar, P.H. Nibbering, J.G. Vanderschroeff, and M. Ponec, Fumaric-acid derivatives evoke a transient increase in intracellular free calcium-concentration and inhibit the proliferation of human keratinocytes. British Journal of Dermatolog., 1994. 131(6): p. 856-61.
257. Litjens, N.H.R., M. Rademaker, B. Ravensbergen, D. Rea, M.J.A. van der Plas, B. Thio, A. Walding, J.T. van Dissel, and P.H. Nibbering, Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in downregulated th1 lymphocyte responses. European Journal of Immunolog., 2004. 34(2): p. 565-75.
258. Vandermeeren, M., S. Janssens, H. Wouters, I. Borghmans, M. Borgers, R. Beyaert, and J. Geysen, Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of nf-kappa b1, but not rela in normal human dermal fibroblast cells. Journal of Investigative Dermatolog., 2001. 116(1): p. 124-30.
259. Nibbering, P.H., B. Thio, A.C. Bezemer, R.L. Beijersbergen, and T.P.L. Zomerdijk, Intracellular signalling by binding sites for the antipsoriatic agent monomethylfumarate on human granulocytes. British Journal of Dermatology, 1997. 137(1): p. 65-75.
260. Nibbering, P.H., B. Thio, T.P.L. Zomerdijk, A.C. Bezemer, R.L. Beijersbergen, and R. Vanfurth, Effects of monomethylfumarate on human granulocytes. Journal of Investigative Dermatolog., 1993. 101(1): p. 37-42.
261. Tang, H., J.Y.-L. Lu, X. Zheng, Y. Yang, and J.D. Reagan, The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem. Biophys. Res. Commun., 2008. 375(4): p. 562-5.
262. Offermanns, S., S.L. Colletti, T.W. Lovenberg, G. Semple, A. Wise, and A.P. Ijzerman, International union of basic and clinical pharmacology. Lxxxii: Nomenclature and classification of hydroxy-carboxylic acid receptors (gpr81, gpr109a, and gpr109b). Pharmacological Review., 2011. 63(2): p. 269-90.
263. Hanson, J., A. Gille, and S. Offermanns, Role of hca(2) (gpr109a) in nicotinic acid and fumaric acid ester-induced effects on the skin. Pharmacology and Therapeutic., 2012. 136(1): p. 1-7.
264. Wallbrecht, K., N. Drick, A.C. Hund, and M.P. Schon, Downregulation of endothelial adhesion molecules by dimethylfumarate, but not monomethylfumarate, and impairment of dynamic lymphocyte-endothelial cell interactions. Experimental Dermatolog., 2011. 20(12): p. 980-5.
265. Garcia-Caballero, M., M. Mari-Beffa, M.A. Medina, and A.R. Quesada, Dimethylfumarate inhibits angiogenesis in vitro and in vivo: A possible role for its antipsoriatic effect? Journal of Investigative Dermatology, 2011. 131(6): p. 1347-55.
266. Meissner, M., E.M. Valesky, S. Kippenberger, and R. Kaufmann, Dimethyl fumarate only an anti-psoriatic medication? Journal Der Deutschen Dermatologischen Gesellschaft, 2012. 10(11): p. 793-802.
267. Barth, D., J.C. Simon, and T. Wetzig, Malignant melanoma during treatment with fumaric acid esters -coincidence or treatment-related? Journal Der Deutschen Dermatologischen Gesellschaft, 2011. 9(3): p. 223-4.
268. Croxtall, J.D., Ustekinumab: A review of its use in the management of moderate to severe plaque psoriasis. Drugs, 71(13): p. 1733-53.